This is fair assessment. I’m personally happy with my investment risk here as the newly released proteomics sheds light on a well known adjacency pathway (think phosphokinase pi3k regulation in precision oncology etc.) in relation to the growth factors and precursory peptides that ATL1102 seems to regulate. A larger cohort size with a higher dose stratum should yield some interesting results. I do agree that the most exciting take away from the P2A is the maintenance or improvement in test scores amongst the majority of subjects.
This is fair assessment. I’m personally happy with my investment...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.5¢ | $18.25K | 237.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18038 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
-0.001 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.0¢ | 7.5¢ | 59548 | ||
| Last updated 15.20pm 10/05/2024 ? | |||||
| PER (ASX) Chart |